Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-B Trial on October 26, 2026 Oct 25, 2026 12:00PM

MENLO PARK, Calif., Oct. 25, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis (PsO) and hidradenitis suppurativa (HS), today announced it will report Week 16 data for ORKA-001 from the ongoing EVERLAST-B Phase 2b trial in moderate-to-severe plaque psoriasis on Monday, October... (continue reading...)


Roche’s divarasib demonstrated best-in-class efficacy, advancing the standard of care in previously treated KRAS G12C-mutated lung cancer Oct 25, 2026 11:30AM
  • Divarasib monotherapy demonstrated superior efficacy over first-generation KRAS G12C inhibitors, lowering the risk of disease progression or death by 42% and the overall risk of death by 44%, in the phase III Krascendo 1 study1,2
  • At the time of primary analysis, divarasib achieved a median overall survival of approximately 18 months, compared to 12 months for sotorasib or adagrasib1,2
  • No new safety signals were observed with divarasib; the most common treatment-related... (continue reading...)

Leads Biolabs' LBL-034 Shows 21.8-Month Median PFS in First-in-Human RRMM Data at ESMO 2026, Validating Its Proprietary TCE Platform Oct 25, 2026 10:29AM

Updated Results Show Deep and Durable Responses in High-Risk, Heavily Pretreated Multiple Myeloma, Supporting Further Development of the Company’s TCE Pipeline

NANJING, China, Oct. 25, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs”, Stock Code: 9887.HK) today announced updated first‑in‑human clinical data for LBL‑034, its GPRC5D/CD3 bispecific T‑cell engager (TCE). The updated results were delivered in an oral presentation at the 2026 Annual... (continue reading...)


Leads Biolabs' LBL-034 Shows 21.8-Month Median PFS in First-in-Human RRMM Data at ESMO 2026, Validating Its Proprietary TCE Platform Oct 25, 2026 10:29AM

NANJING, China, Oct. 25, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs”, Stock Code: 9887.HK) today announced updated first‑in‑human clinical data for LBL‑034, its GPRC5D/CD3 bispecific T‑cell engager (TCE). The updated results were delivered in an oral presentation at the 2026 Annual Meeting of the European Society for Medical Oncology (ESMO), showcasing compelling efficacy and safety outcomes in patients with relapsed/refractory multiple... (continue reading...)


Crypto News: Remittix Announces 300 Million RTX Burn at Launch as JPMorgan Brings Two Tokenized Funds to Solana, Building the Case for a $300 SOL Price Prediction Oct 25, 2026 09:50AM

Remittix prepares to remove 20% of its original token supply as JPMorgan expands institutional access to Solana through two tokenized money market funds.

MAJURO, Marshall Islands, Oct. 25, 2026 (GLOBE NEWSWIRE) -- Remittix has announced plans to burn 300 million RTX tokens at launch, removing 20% of its original supply as the project approaches its November 24, 2026 market debut. The burn brings a major tokenomics milestone into the final launch window alongside... (continue reading...)


More Globe Newswire

View Older Stories

Oct 25, 2026 09:00AM ArriVent Announces Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at ESMO Congress 2026
Oct 25, 2026 08:11AM Amarin Provides Update on University of Leeds Sponsored Phase 3 EPA for Metastasis Trial 2 (EMT2) Evaluating VAZKEPA®/VASCEPA® (icosapent ethyl) Capsules on Top of Standard of Care Treatment in Pati
Oct 25, 2026 07:27AM AirTripMaker Launches Comprehensive Flight Tickets to India Routes Guide from the USA and Canada to Major Indian Destinations
Oct 25, 2026 07:00AM NovaBridge Biosciences Reports Mature Phase 1b Data at ESMO 2026 Positioning Givastomig for Registrational Development
Oct 25, 2026 07:00AM Genmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal Cancer
Oct 25, 2026 06:26AM Beyond Live Streaming: Tango Gives Back by Supporting Cancer Detection in Ukraine
Oct 25, 2026 06:22AM SI vs. AI: Super Intelligence Anomaly Outbreaks Trump’d by Clinton Legacy Tech (Veterans First for America)
Oct 25, 2026 05:15AM Libtayo® (cemiplimab) Longer-Term Data Show Increasing and Clinically Meaningful Overall Survival Benefit with Adjuvant Treatment in High-Risk Cutaneous Squamous Cell Carcinoma (CSCC)
Oct 25, 2026 05:00AM KFSH Expands Virtual Care Pathways to Bring Specialized Follow-Up Closer to Patients
Oct 25, 2026 03:30AM BioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 Data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus Chemotherapy
Oct 24, 2026 07:30PM Climb Bio Presents Initial PrisMN Phase 2 Data from Budoprutug in pMN at an Oral Session at ASN Kidney Week 2026
Oct 24, 2026 03:18PM Teck Provides Update on Highland Valley Copper Operations
Oct 24, 2026 02:00PM Online Cricket ID App Publishes Overview of Changing Digital Cricket Information Needs Among Indian Fans
Oct 24, 2026 01:56PM UK Financial Ltd Launches MAYA CHAIN and Begins Digital Asset Migration
Oct 24, 2026 01:10PM Get Cricket IDs Announces Online Information Resources for Live Cricket Updates, Match Statistics and Mobile Platform Access
Oct 24, 2026 12:35PM AI-119 Vulcan Force Solution Targets California's May 2027 Frontier AI Deadline (Veterans First for America)
Oct 24, 2026 12:35PM AI-119 Vulcan Force Solution Targets California's May 2027 Frontier AI Deadline (Veterans First for America)
Oct 24, 2026 10:00AM Melbourne coach Dominik Kulewski's Weight Loss Lab clients have now lost about 3 tonnes combined
Oct 24, 2026 10:00AM Melbourne coach Dominik Kulewski's Weight Loss Lab clients have now lost about 3 tonnes combined
Oct 24, 2026 09:28AM Widgets & Web Launches AI-Operated Investor Relations Websites for Public Companies at a Fixed $299 per Month
Oct 24, 2026 09:28AM Widgets & Web Launches AI-Operated Investor Relations Websites for Public Companies at a Fixed $299 per Month
Oct 24, 2026 09:00AM 2026 National Poppy Campaign launches with a donation “first” … and stunning mural: Don’t forget to Remember
Oct 24, 2026 09:00AM Thousands of Ontarians to Attend ‘Together for Publicly Funded Education’ Rallies
Oct 24, 2026 08:45AM Quanta Presents Positive Clinical Combination Data in KRAS G12D-Mutant CRC at ESMO and Highlights Pan-KRAS Progress
Oct 24, 2026 08:45AM Parabilis Medicines Presents Updated Phase 1/2 Data for Zolucatetide Demonstrating Compelling Efficacy and Favorable Safety and Tolerability Profile in Patients with Desmoid Tumors
Oct 24, 2026 08:20AM DEEP Robotics Unveils Five Research Advances in Embodied AI
Oct 24, 2026 08:09AM JST Buyback & Burn Upgrade: GasFree Revenue and $20.34M Surplus Injected as JUST's Ecosystem Trio Solidifies JST Token Value
Oct 24, 2026 08:09AM JST Buyback & Burn Upgrade: GasFree Revenue and $20.34M Surplus Injected as JUST's Ecosystem Trio Solidifies JST Token Value
Oct 24, 2026 07:00AM NANOBIOTIX Announces Final Data from Phase 1 Study Evaluating JNJ-1900 (NBTXR3) With Immune Checkpoint Inhibitors as a 2L+ Therapy in Anti-PD-1-Resistant Primary Cutaneous Melanoma
Oct 24, 2026 07:00AM Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer
Oct 24, 2026 06:47AM Asyad Group to Host Muscat Maritime Resilience Forum to Strengthen Global Trade Networks
Oct 24, 2026 05:00AM KFSH Extends Emergency Access Through Virtual Care and Specialist Coordination
Oct 24, 2026 04:47AM AirTripMaker Launches Comprehensive Business Class Flight Routes Guide from the USA to 15 Major International Destinations and Regions
Oct 24, 2026 04:15AM Celcuity Presents Updated Results from the PIK3CA MT Cohort of the Phase 3 VIKTORIA-1 Study in Patients with HR+/HER2- Advanced Breast Cancer at the ESMO Congress 2026
Oct 24, 2026 04:15AM Compass Therapeutics Announces Publication of Phase 2/3 COMPANION-002 Results for Tovecimig in the Journal of Clinical Oncology and Oral Presentation at ESMO 2026
Oct 24, 2026 02:35AM Darolutamide plus ADT and radiation therapy reduces risk of metastasis or death by 58% in prostate cancer patients at high risk of recurrence
Oct 24, 2026 02:30AM Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026
Oct 24, 2026 02:30AM Immatics Presents Clinical Activity of IMA402 PRAME Bispecific and IMA203CD8 PRAME Cell Therapy across Advanced Solid Tumors in Two Oral Presentations at 2026 ESMO Annual Meeting
Oct 24, 2026 02:25AM Yangguang News Launches Global Youth Short Video Campaign “Me, Tang Poetry, and AI”
Oct 24, 2026 12:44AM World Famous Liquor Brands Sustainability Index Report (2026) Released
Oct 24, 2026 12:17AM Rooted in the River, Renewed with the Times: Insights from the 2026 Chishui River Forum
Oct 23, 2026 11:30PM Junshi Biosciences Announces Completion of First Patient Dosing in the Phase 3 Clinical Trial of JS203 in Combination with Chemotherapy for the Treatment of Diffuse Large B-cell Lymphoma
Oct 23, 2026 10:06PM See It, Try It, Compare It: SIVP Brings CHERY’s “Technology. For Family” to Life
Oct 23, 2026 10:00PM Vmake Labs Launches All-in-One Halloween Social Video Toolkit for SMBs
Oct 23, 2026 09:50PM Amaggi Luxembourg International S.à r.l. Announces Expiration and Results of Its Cash Tender Offer for Up to U.S.$300 Million Aggregate Principal Amount of Its 5.250% Notes Due 2028
Oct 23, 2026 09:23PM Urban Seed Logs Record Harvest in 15th Season, Sets 2027 Focus on Building an Organization That Lasts
Oct 23, 2026 09:21PM SuperClean Restoration Of The Palm Beaches LLC Surpasses 100+ Google Reviews, Solidifying Its Reputation as the Most Trusted Name in Water Damage Restoration in Wellington, FL
Oct 23, 2026 08:30PM Shalaan Umar is America’s Top Young Innovator 2026 as Young Inventors Earn Global Recognition for Breakthrough Innovations
Oct 23, 2026 08:00PM RxSight Reports Inducement Grants as Permitted by the Nasdaq Listing Rules
Oct 23, 2026 07:01PM Reid Collins & Tsai LLP Notifies Holders of Navios Maritime Holdings, Inc.’s Preferred ADS of Deficiencies in Navios’s Recent Tender Offer Documentation
View Older Stories